Courses Free Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 – The webinar will be available soon Enroll Now Free PTCy-based graft-versus-host disease prophylaxis for matched sibling donor – Tuesday, March 4, 2025 Enroll Now Free Pioneers in Hematology: Dr Thierry Facon – Monday, January 6, 2025 Enroll Now Free Long-term complications of chronic GVHD – Wednesday, January 15, 2025 Enroll Now Free CAR T-cells for AML: Where do we stand? Enroll Now Free How to Get Published: a Few Tips Enroll Now Free CD47 : From bench to bedside? Enroll Now Free Management of Waldenström’s Disease: An Update Enroll Now Free Transplant Indications in Lymphoma: Where Are We? Enroll Now Free IACH 2025 Scientific Program course Enroll Now Free Management of chronic GVHD – Monday, December 16, 2024 Enroll Now Free Diagnosis and grading of chronic GVHD – Monday, November 25, 2024 Enroll Now Free Diagnosis and management of acute GVHD – Monday, November 4, 2024 Enroll Now Free Acute and Chronic GVHD pathophysiology – Oct 7, 2024 Enroll Now Free COMy 2025 Scientific Program course Enroll Now Free Early transplant complications: a focus on VOD diagnosis Enroll Now Free Diagnosis and management of chronic GVHD Enroll Now Free Chronic GVHD: prevention and management of long-term complications Enroll Now Free Diagnosis and management of acute GVHD Enroll Now Free Optimal GVHD prophylaxis Enroll Now « ‹ › » page 1 / 2
Free Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial – Monday, March 24, 2025 – The webinar will be available soon Enroll Now
Free PTCy-based graft-versus-host disease prophylaxis for matched sibling donor – Tuesday, March 4, 2025 Enroll Now